APP and Alzheimer disease: NEP and IDE levels were aberrantly decreased at the dementia stage of AD patients, but not in the preclinical stage of AD patients, and the same results were also found in the APP/PS1 mice [45–47], suggesting that Aβ-degrading activities are gradually reduced after disease onset in AD.